Best overall response
| Patients . | n . | ORR (≥ PR), n (%) . | CBR (≥ MR), n (%) . | CR, n (%) . | VGPR, n (%) . | PR, n (%)* . | MR, n (%) . | SD, n (%) . | PD, n (%) . |
|---|---|---|---|---|---|---|---|---|---|
| All patients | 40 | 25 (63) | 32 (80) | 3 (8) | 9 (23) | 13 (33) | 7 (18) | 7 (18) | 1 (3) |
| Dose escalation patients | 16 | 11 (69) | 13 (81) | 2 (13) | 4 (25) | 5 (31) | 2 (13) | 2 (13) | 1 (3) |
| RP2D patients | 24 | 14 (58) | 19 (79) | 1 (4) | 5 (21) | 8 (33) | 5 (21) | 5 (21) | — |
| PI nonrefractory | 19 | 16 (84) | 18 (95) | 2 (11) | 5 (26) | 9 (47) | 2 (11) | 1 (5) | — |
| PI refractory | 21 | 9 (43) | 14 (67) | 1 (5) | 4 (19) | 4 (19) | 5 (24) | 6 (29) | 1 (5) |
| PI and IMiD refractory | 19 | 8 (42) | 12 (63) | — | 4 (21) | 4 (21) | 4 (21) | 6 (32) | 1 (5) |
| Patients . | n . | ORR (≥ PR), n (%) . | CBR (≥ MR), n (%) . | CR, n (%) . | VGPR, n (%) . | PR, n (%)* . | MR, n (%) . | SD, n (%) . | PD, n (%) . |
|---|---|---|---|---|---|---|---|---|---|
| All patients | 40 | 25 (63) | 32 (80) | 3 (8) | 9 (23) | 13 (33) | 7 (18) | 7 (18) | 1 (3) |
| Dose escalation patients | 16 | 11 (69) | 13 (81) | 2 (13) | 4 (25) | 5 (31) | 2 (13) | 2 (13) | 1 (3) |
| RP2D patients | 24 | 14 (58) | 19 (79) | 1 (4) | 5 (21) | 8 (33) | 5 (21) | 5 (21) | — |
| PI nonrefractory | 19 | 16 (84) | 18 (95) | 2 (11) | 5 (26) | 9 (47) | 2 (11) | 1 (5) | — |
| PI refractory | 21 | 9 (43) | 14 (67) | 1 (5) | 4 (19) | 4 (19) | 5 (24) | 6 (29) | 1 (5) |
| PI and IMiD refractory | 19 | 8 (42) | 12 (63) | — | 4 (21) | 4 (21) | 4 (21) | 6 (32) | 1 (5) |
The ORR and CBR were applied for all evaluable patients (n = 40). Two patients did not have sufficient disease measurements after 1 cycle of treatment and were therefore considered nonevaluable.
Includes 1 unconfirmed PR.